Cytophage Announces Non-Brokered Private Placement

Executive Summary

• Cytophage Technologies announced a non‑brokered private placement of up to 6,000,000 units at C$0.20 per unit, targeting gross proceeds of up to C$1,200,000, with an optional additional raise of C$600,000.
• Each unit consists of one common share and half of a common‑share purchase warrant (full warrant = right to buy one share at C$0.40 for 24 months); the company may also issue finder’s warrants up to 7 % of units sold.
• Net proceeds will be used to advance phage technology programs in human health, animal health and food security and for general corporate purposes; closing expected around November 6 2025 pending TSX‑V approval.

Key Details

• Offering Size: Up to 6,000,000 units (C$0.20 per unit) → up to C$1,200,000 gross proceeds.
• Optional Upside: Company may increase the offering by up to an additional C$600,000 (3,000,000 extra units).
• Unit Composition: 1 common share + ½ of a common‑share purchase warrant. Full warrant allows purchase of one additional share at C$0.40 for 24 months.
• Acceleration Right: Warrants may be accelerated if TSX‑V VWAP ≥ C$0.60 for 10 consecutive trading days; acceleration effected by notice to warrant holders.
• Finder’s Fees & Warrants: Up to 7 % of gross proceeds may be paid as finder’s fees; up to 7 % of units sold may be issued as “Finder’s Warrants” (exercise price C$0.40, same acceleration terms).
• Hold Period: All securities subject to a hold period expiring 4 months + 1 day after each closing date per TSX‑V rules.
• Use of Proceeds: Advance cutting‑edge phage technology for human health, animal health, food security; general corporate purposes.
• Closing Timeline: Anticipated on or about November 6 2025, subject to TSX‑V regulatory approvals; may be closed in multiple tranches.
• CEO Comment: Dr. Steven Theriault highlighted recent EU pilot studies and Canadian regulatory advances, stating the financing will enable critical milestones for AviPhage and OvaPhage commercialization.

Notable Quotes

“We are proud of the strong momentum that we have had with our two recent pilot studies in the EU, and regulatory advances in Canada with our OvaPhage and PhageFend products. This financing will enable Cytophage to achieve critical milestones that relate to its AviPhage and OvaPhage commercialization.” – Dr. Steven Theriault, CEO